- Home
- AGEN vs FBIO Comparison
AGEN vs FBIO Comparison
Compare AGEN & FBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AGEN
- FBIO
- Stock Information
- Founded
- AGEN 1994
- FBIO 2006
- Country
- AGEN United States
- FBIO United States
- Employees
- AGEN N/A
- FBIO N/A
- Industry
- AGEN Biotechnology: Biological Products (No Diagnostic Substances)
- FBIO Biotechnology: Pharmaceutical Preparations
- Sector
- AGEN Health Care
- FBIO Health Care
- Exchange
- AGEN Nasdaq
- FBIO Nasdaq
- Market Cap
- AGEN 52.6M
- FBIO 49.1M
- IPO Year
- AGEN 2000
- FBIO N/A
- Fundamental
- Price
- AGEN $2.91
- FBIO $1.69
- Analyst Decision
- AGEN Buy
- FBIO Strong Buy
- Analyst Count
- AGEN 4
- FBIO 3
- Target Price
- AGEN $8.00
- FBIO $21.00
- AVG Volume (30 Days)
- AGEN 830.5K
- FBIO 144.5K
- Earning Date
- AGEN 05-12-2025
- FBIO 05-19-2025
- Dividend Yield
- AGEN N/A
- FBIO N/A
- EPS Growth
- AGEN N/A
- FBIO N/A
- EPS
- AGEN N/A
- FBIO N/A
- Revenue
- AGEN $103,463,000.00
- FBIO $57,675,000.00
- Revenue This Year
- AGEN $4.03
- FBIO $63.20
- Revenue Next Year
- AGEN $5.57
- FBIO $66.70
- P/E Ratio
- AGEN N/A
- FBIO N/A
- Revenue Growth
- AGEN N/A
- FBIO N/A
- 52 Week Low
- AGEN $1.38
- FBIO $1.33
- 52 Week High
- AGEN $19.69
- FBIO $2.89
- Technical
- Relative Strength Index (RSI)
- AGEN 59.81
- FBIO 52.97
- Support Level
- AGEN $2.87
- FBIO $1.67
- Resistance Level
- AGEN $3.16
- FBIO $1.84
- Average True Range (ATR)
- AGEN 0.35
- FBIO 0.09
- MACD
- AGEN 0.02
- FBIO 0.01
- Stochastic Oscillator
- AGEN 56.25
- FBIO 58.54
About AGEN Agenus Inc.
Agenus Inc is an American clinical-stage company with a pipeline of therapies designed to activate the body's immune system to fight cancer and infections, including immune-modulatory antibodies, adoptive cell therapies through its subsidiary MiNK Therapeutics Inc. and vaccine adjuvants through its subsidiary SaponiQx Inc. This robust product pipeline is supported by company's in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. The company's antibody candidates are botensilimab (a proprietary next-generation Fc-engineered CTLA-4 antibody, also known as AGEN1811) and balstilimab (a PD-1 antibody).
About FBIO Fortress Biotech Inc.
Fortress Biotech Inc is a biopharmaceutical company. The firm is involved in the business of acquiring, developing, and commercializing pharmaceutical and biotechnology products. Its product portfolio encompasses Qbrexza, Accutane, Amzeeq, Zilxi, Targadox, Ximino, and Exelderm. The business activities of the group are functioned through Dermatology Product Sales, and Pharmaceutical and Biotechnology Product Development. It derives the majority of its revenues from Dermatology segment. Its subsidiaries also operate in biotechnology, pharmaceutical, oncology and therapeutics sectors.